Price movement over the last 24 hours
Abeona Therapeutics Inc vs Ecopetrol SA — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Ecopetrol SA trades at $15.15 (market cap $28.19B). The key difference: Ecopetrol SA is far larger — about 75.5× Abeona Therapeutics Inc's market cap, and Ecopetrol SA pays a 4.42% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EC | |
|---|---|---|
Market Cap | $373.32M | $28.19B |
Sector | Health | Energy |
52-Week High | $7.23 | $16.58 |
52-Week Low | $4.17 | $8.29 |
Enterprise Value | $228.22M | $55.97B |
Dividend Yield | — | 4.42% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ecopetrol (EC) trades at $14.69, slightly below the consensus price target of $14.63, with a bearish technical signal and mixed earnings performance. Recent quarters show misses against EPS expectations, while revenue has declined from $159.6T in 2022 to $119.7T in 2025. The company maintains a dividend payout, with a recent H1-26 dividend of $0.66, and holds a BB- credit rating with a stable outlook as affirmed by S&P Global Ratings on June 17, 2026.
The outlook remains cautious due to declining revenue and profitability trends, offset by attractive valuation multiples like a P/E of 10.31. Key risks include operational execution in the energy sector and macroeconomic pressures on oil demand. Analyst sentiment is mixed with a Hold-dominated consensus, suggesting limited near-term upside potential amid ongoing fundamental challenges.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →